enzyme-design
(2)
Ridge Bio
Ridge Biotechnologies is a Bay Area startup using AI-driven enzyme and targeted drug design to build the next generation of precision medicines. Its platform pairs proprietary machine learning models with high-throughput, cell-free wet-lab experimentation to design enzymes and delivery systems for applications spanning antibody-drug conjugates, in vivo CAR-T, targeted nucleic acid delivery, biocatalysis and radiotherapies. The company emerged from stealth in September 2025 with an oversubscribed $25 million seed round led by Sutter Hill Ventures.
Weston Kightlinger
Weston Kightlinger is the CEO and co-founder of Ridge Bio (Ridge Biotechnologies), a Palo Alto biotech that left stealth in September 2025 with $25 million in seed funding to design precision enzymes and targeted therapeutics by pairing machine learning with massive cell-free laboratory datasets. A Northwestern-trained scientist with a background in cell-free protein synthesis and protein glycosylation, he turned a decade of bench work into a company whose advisory board reads like a who's-who of chemical biology, including Nobel laureate Carolyn Bertozzi.